Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Atypical Pneumonia01:14

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pyrazinamide susceptibility testing in <i>Mycobacterium tuberculosis</i>: impact of false-positive BD MGIT 960 results and added value of sequencing for accurate diagnosis in a low-MDR-TB-incidence context.

Frontiers in cellular and infection microbiology·2026
Same author

Sickle cell disease-associated pulmonary hypertension: an integrated framework linking pathologies, mechanisms, and clinical phenotypes.

EBioMedicine·2026
Same author

Economic burden of pulmonary arterial hypertension in Switzerland.

PloS one·2026
Same author

The Role of Nontuberculous Mycobacteria in Patients With Cystic Fibrosis Advanced Lung Disease.

Transplant infectious disease : an official journal of the Transplantation Society·2026
Same author

Pulmonary hypertension associated with hereditary haemorrhagic telangiectasia: from genetics to clinical management.

The European respiratory journal·2026
Same author

Establishing an Entrustable Professional Activity-Based Curriculum for Postgraduate Respiratory Medicine Training: A National Consensus Process.

Respiration; international review of thoracic diseases·2026

Related Experiment Video

Updated: May 24, 2026

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates
10:04

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates

Published on: September 5, 2017

[Latent M. tuberculosis infection, update 2011].

Benoît Lechartier1, Jesica Mazza-Stalder, Jean-Paul Janssens

  • 1Service de pneumologie Département de médecine, CHUV, 1011 Lausanne. benoit.lechartier@chuv.ch

Revue Medicale Suisse
|March 10, 2012
PubMed
Summary
This summary is machine-generated.

Latent tuberculosis (TB) is a significant health concern, particularly in Switzerland, where diagnosis and treatment are often insufficient, especially for immunocompromised individuals. Shorter, alternative treatments like rifampicin show promise for improved adherence and cost-effectiveness.

More Related Videos

A 3D Human Lung Tissue Model for Functional Studies on Mycobacterium tuberculosis Infection
10:10

A 3D Human Lung Tissue Model for Functional Studies on Mycobacterium tuberculosis Infection

Published on: October 5, 2015

A Novel Microdissection Approach to Recovering Mycobacterium tuberculosis Specific Transcripts from Formalin Fixed Paraffin Embedded Lung Granulomas
07:42

A Novel Microdissection Approach to Recovering Mycobacterium tuberculosis Specific Transcripts from Formalin Fixed Paraffin Embedded Lung Granulomas

Published on: June 5, 2014

Related Experiment Videos

Last Updated: May 24, 2026

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates
10:04

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates

Published on: September 5, 2017

A 3D Human Lung Tissue Model for Functional Studies on Mycobacterium tuberculosis Infection
10:10

A 3D Human Lung Tissue Model for Functional Studies on Mycobacterium tuberculosis Infection

Published on: October 5, 2015

A Novel Microdissection Approach to Recovering Mycobacterium tuberculosis Specific Transcripts from Formalin Fixed Paraffin Embedded Lung Granulomas
07:42

A Novel Microdissection Approach to Recovering Mycobacterium tuberculosis Specific Transcripts from Formalin Fixed Paraffin Embedded Lung Granulomas

Published on: June 5, 2014

Area of Science:

  • Public Health
  • Infectious Diseases
  • Epidemiology

Background:

  • An estimated one-third of the global population harbors latent Mycobacterium tuberculosis infection, posing a significant reactivation risk.
  • Latent tuberculosis (TB) and its impact in Switzerland are frequently underestimated, leading to inadequate diagnosis and prophylaxis.
  • Immunosuppressed individuals represent a high-risk group for TB reactivation, necessitating targeted screening and preventive strategies.

Purpose of the Study:

  • To highlight the overlooked burden of latent TB in Switzerland.
  • To emphasize the need for improved diagnosis and prophylaxis, particularly in high-risk populations.
  • To evaluate current and alternative treatment options for latent TB.

Main Methods:

  • Review of diagnostic approaches, including the shift from tuberculosis skin tests to interferon-gamma release assays for adults.
  • Analysis of prophylactic treatment regimens for latent TB infection.
  • Assessment of adherence, cost-benefit, and efficacy of different treatment durations and medications.

Main Results:

  • Interferon-gamma release assays are now the standard for diagnosing latent TB in adults.
  • While 9 months of isoniazid remains a recommended prophylactic treatment, a 4-month rifampicin regimen is a viable alternative.
  • The rifampicin regimen demonstrates improved patient adherence and a favorable cost-benefit ratio compared to isoniazid.

Conclusions:

  • There is a critical need to enhance latent TB diagnosis and prophylaxis efforts in Switzerland.
  • The 4-month rifampicin treatment offers a practical and effective alternative for latent TB management, improving adherence and cost-effectiveness.
  • Targeted interventions for high-risk, immunosuppressed populations are essential to reduce TB reactivation rates.